Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting
28 Fevereiro 2019 - 10:30AM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced seven presentations at the 2019
American Association for Cancer Research (AACR) Annual Meeting
being held March 29-April 3, 2019 in Atlanta, Georgia.
Details of Arcus’s Presentations are as
follows:
ORAL PRESENTATION:
AB680 (small-molecule CD73
inhibitor)
Title: Development of potent and selective CD73
inhibitors: Discovery and characterization of AB680Date and
Time: Saturday, March 30, 2019, 9:30 AM - 9:55
AMLocation: Room A311
POSTER PRESENTATIONS:
AB928 (dual A2aR/A2bR antagonist)
Title: Methods for assessment of the “adenosine
fingerprint” in clinical trials of AB928Abstract Number:
3168Date and Time: Tuesday, April 2, 2019, 8:00 AM -
12:00 PMLocation: Exhibit Hall B, Poster Section: 21,
Poster Board Number: 21
Title: Altered pan-Ras pathway and activating mutations
in EGFR result in elevated CD73 in multiple cancersAbstract
Number: 4980Date and Time: Wednesday, April 3,
2019, 8:00 AM - 12:00 PMLocation: Exhibit Hall B,
Poster Section: 24, Poster Board Number: 3
AB122 (anti-PD-1 antibody)
Title: Longitudinal monitoring of neoepitope-specific T
cell repertoires in patient blood following cancer
immunotherapyAbstract Number: 4042Date and
Time: Tuesday, April 2, 2019, 1:00 PM - 5:00
PMLocation: Exhibit Hall B, Poster Section: 22, Poster
Board Number: 5
Title: Receptor occupancy and neo-epitope specific
T-cell repertoires in patients with solid tissue tumors following
anti-PD-1 therapyAbstract Number: 4100Session Date and
Time: Tuesday, April 2, 2019, 1:00 PM - 5:00
PMLocation: Exhibit Hall B, Poster Section: 24,
Poster Board Number: 3
AB154 (anti-TIGIT antibody)
Title: Characterization of AB154, a humanized α-TIGIT
antibody, for use in combination therapiesAbstract Number:
1557Session Date and Time: Monday, April 1, 2019, 8:00
AM - 12:00 PMLocation: Exhibit Hall B, Poster Section:
25, Poster Board Number: 26
AB474 (arginase inhibitor)
Title: AB474, a potent orally bioavailable inhibitor of
arginase, for the treatment of cancerAbstract Number:
3862Date and Time: Tuesday, April 2, 2019, 1:00 PM -
5:00 PMLocation: Exhibit Hall B, Poster Section: 12, Poster
Board Number: 12
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist, AB928, which is in
a Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody, AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small-molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about
Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190228005221/en/
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024